BRIEF

on OXURION (EBR:OXUR)

Axiodis CRO is boosting its strategy to achieve sustained growth

Stock price chart of OXURION (EBR:OXUR) showing fluctuations.

On February 16, 2026, Axiodis CRO, an Oxurion subsidiary specializing in clinical data management, announced a major strategic shift. The company is undertaking a commercial and marketing transformation, supported by the recruitment of new talent and a redesign of its website. The goal: to double its revenue by 2028, from €928,000 to €2 million.

Efforts are focused on a dedicated sales team, targeting high-value segments such as pharmaceutical and biotech sponsors. In parallel, Axiodis is strengthening its visibility with a new marketing manager and optimizing its offering for an improved customer experience.

Furthermore, Axiodis is exploring synergies with a company specializing in clinical operations to offer comprehensive integrated solutions. The use of artificial intelligence is also central to Axiodis' innovations, with ongoing pilot projects aimed at transforming medical writing and nutritional prescribing through AI.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all OXURION news